{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:47:44Z","timestamp":1792597664778,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019590","name":"Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-026-05446-1","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:22:53Z","timestamp":1784974973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vitro and in vivo antibacterial activity of pravibismane against Mycobacteroides abscessus"],"prefix":"10.1186","volume":"26","author":[{"given":"Amy","family":"Leestemaker-Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz E.","family":"Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett H. J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"5446_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MCP.0000000000000816","volume":"27","author":"JA Nick","year":"2021","unstructured":"Nick JA, Daley CL, Lenhart-Pendergrass PM, Davidson RM. Nontuberculous mycobacteria in cystic fibrosis. Curr Opin Pulm Med. 2021;27:586\u201392.","journal-title":"Curr Opin Pulm Med"},{"key":"5446_CR2","first-page":"817","volume":"15","author":"J Adjemian","year":"2018","unstructured":"Adjemian J, Olivier KN, Prevots DR. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014. undefined. 2018;15:817\u201325.","journal-title":"undefined"},{"key":"5446_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"5446_CR4","doi-asserted-by":"crossref","unstructured":"Gross JE, Caceres S, Poch K, Hasan NA, Jia F, Epperson LE, Lipner E, Vang C, Honda JR, Strand M, de Moura VCN, Daley CL, Strong M, Davidson RM, Nick JA. Investigating nontuberculous mycobacteria transmission at the Colorado adult cystic fibrosis program. Am J Respir Crit Care Med. 2022;205:1064\u201374.","DOI":"10.1164\/rccm.202108-1911OC"},{"key":"5446_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1164\/rccm.201807-1273PP","volume":"199","author":"S Daniel-Wayman","year":"2019","unstructured":"Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research. Am J Respir Crit Care Med. 2019;199:947\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"5446_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41370-021-00360-2","volume":"32","author":"EM Lipner","year":"2022","unstructured":"Lipner EM, Crooks JL, French J, Strong M, Nick JA, Prevots DR. Nontuberculous mycobacterial infection and environmental molybdenum in persons with cystic fibrosis: a case\u2013control study in Colorado. J Expo Sci Environ Epidemiol. 2022;32:289\u201394.","journal-title":"J Expo Sci Environ Epidemiol"},{"key":"5446_CR7","doi-asserted-by":"crossref","unstructured":"Davidson RM. A closer look at the genomic variation of geographically diverse mycobacterium abscessus clones that cause human infection and disease. Front Microbiol. 2018;9:2988.","DOI":"10.3389\/fmicb.2018.02988"},{"key":"5446_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1093\/jac\/dkr578","volume":"67","author":"R Nessar","year":"2012","unstructured":"Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67:810\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"5446_CR9","doi-asserted-by":"crossref","unstructured":"Fennelly KP, Ojano-Dirain C, Yang Q, Liu L, Lu L, Progulske-Fox A, Wang GP, Antonelli P, Schultz G. 2016. Biofilm Formation by Mycobacterium abscessus in a Lung Cavity. Am J Respir Crit Care Med. 2016;193:692\u20133.","DOI":"10.1164\/rccm.201508-1586IM"},{"key":"5446_CR10","doi-asserted-by":"crossref","unstructured":"Keefe BF, Bermudez LE. Environment in the lung of cystic fibrosis patients stimulates the expression of biofilm phenotype in Mycobacterium abscessus. J Med Microbiol. 2022;71:001467.","DOI":"10.1099\/jmm.0.001467"},{"key":"5446_CR11","doi-asserted-by":"crossref","unstructured":"Roux AL, Viljoen A, Bah A, Simeone R, Bernut A, Laencina L, Deramaudt T, Rottman M, Gaillard JL, Majlessi L, Brosch R, Girard-Misguich F, Vergne I, de Chastellier C, Kremer L, Herrmann JL. The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages. Open Biol. 2016;6:160185.","DOI":"10.1098\/rsob.160185"},{"issue":"2","key":"5446_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.22207\/JPAM.16.2.41","volume":"16","author":"T Kalpana","year":"2022","unstructured":"Kalpana T, Mugunthan M, Joseph NM, Ellappan K. A Comprehensive Review and Update on Epidemiology, Symptomatology and Management of Nontuberculous Mycobacteria (NTM). J Pure Appl Microbiol. 2022;16(2):814\u201324. https:\/\/doi.org\/10.22207\/JPAM.16.2.41.","journal-title":"J Pure Appl Microbiol"},{"key":"5446_CR13","volume-title":"The Year of the Lung","author":"CL Daley","year":"2010","unstructured":"Daley CL, Griffith DE. Pulmonary non-tuberculous mycobacterial infections [Review article. The Year of the Lung. Series editor: John F. Murray]; 2010."},{"key":"5446_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcf.2009.12.001","volume":"9","author":"CR Esther","year":"2010","unstructured":"Esther CR, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010;9:117\u201323.","journal-title":"J Cyst Fibros"},{"key":"5446_CR15","doi-asserted-by":"publisher","first-page":"e14817","DOI":"10.1111\/iwj.14817","volume":"21","author":"BA Lipsky","year":"2024","unstructured":"Lipsky BA, Kim PJ, Murphy B, McKernan PA, Armstrong DG, Baker BHJ. Topical pravibismane as adjuvant therapy for moderate or severe diabetic foot infections: A phase 1b randomized, multicenter, double-blind, placebo-controlled, trial. Internat Wound J. 2024;21:e14817.","journal-title":"Internat Wound J"},{"key":"5446_CR16","doi-asserted-by":"publisher","first-page":"S659","DOI":"10.1093\/ofid\/ofaa439.1472","volume":"7","author":"B Baker","year":"2020","unstructured":"Baker B. Poster 1289. Pravibismane is a Potent, Broad Spectrum Anti-Infective Small Molecule that Rapidly Disrupts Bacterial Bioenergetics and Halts Bacterial Growth. Open Forum Infect Dis. 2020;7:S659\u201360.","journal-title":"Open Forum Infect Dis"},{"key":"5446_CR17","unstructured":"Zori M, Parsek MR, Hernandez RE, Baker B. Evaluating the antibiofilm activity of pravibismane in cystic fibrosis-related pathogens, 2022-A-352-ASM-BIO. Abstract."},{"key":"5446_CR18","first-page":"e00440","volume":"62","author":"JD Blanchard","year":"2018","unstructured":"Blanchard JD, Elias V, Cipolla D, Gonda I, Bermudez LE. Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin. Antimicrob Agents Chemothapy. 2018;62:e00440\u201318.","journal-title":"Antimicrob Agents Chemothapy"},{"key":"5446_CR19","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","volume":"22","author":"J Raaijmakers","year":"2021","unstructured":"Raaijmakers J, Schildkraut JA, Hoefsloot W, van Ingen J. The role of amikacin in the treatment of nontuberculous mycobacterial disease. Expert Opin Pharmacother. 2021;22:1961\u201374.","journal-title":"Expert Opin Pharmacother"},{"key":"5446_CR20","doi-asserted-by":"crossref","unstructured":"Chen J, Zhao L, Mao Y, Ye M, Guo Q, Zhang Y, Xu L, Zhang Z, Li B, Chu H. Clinical efficacy and adverse effects of antibiotics used to treat mycobacterium abscessus pulmonary disease. Front Microbiol. 2019;10:1977.","DOI":"10.3389\/fmicb.2019.01977"},{"key":"5446_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1128\/AAC.00861-10","volume":"55","author":"S Bastian","year":"2011","unstructured":"Bastian S, Veziris N, Roux A-L, Brossier F, Gaillard J-L, Jrlier V, Cambau E. Ssessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm (41) and rrl sequencing. Antimicrob Agents Chemother. 2011;55:775\u201381.","journal-title":"Antimicrob Agents Chemother"},{"key":"5446_CR22","doi-asserted-by":"publisher","unstructured":"Kumar K, Daley CL, Griffith DE, Loebinger MR. Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments https:\/\/doi.org\/10.1183\/16000617.0212-2021.","DOI":"10.1183\/16000617.0212-2021"},{"key":"5446_CR23","doi-asserted-by":"publisher","first-page":"e108703","DOI":"10.1371\/journal.pone.0108703","volume":"9","author":"SJ Rose","year":"2014","unstructured":"Rose SJ, Neville ME, Gupta R, Bermudez LE. Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection. PLoS ONE. 2014;9:e108703.","journal-title":"PLoS ONE"},{"key":"5446_CR24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","volume":"195","author":"KN Olivier","year":"2017","unstructured":"Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017;195:814\u201323.","journal-title":"Am J Respir Crit Care Med"},{"key":"5446_CR25","doi-asserted-by":"crossref","unstructured":"Lewis MS, Danelishvili L, Rose SJ, Bermudez LE. 2019. MAV_4644 Interaction with the Host Cathepsin Z Protects Mycobacterium avium subsp. hominissuis from Rapid Macrophage Killing. Microorganisms. 2019;7:149\u2013168.","DOI":"10.3390\/microorganisms7050144"},{"key":"5446_CR26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1080\/08958370802207318","volume":"20","author":"DJ Alexander","year":"2008","unstructured":"Alexander DJ, Collins CJ, Coombs DW, Gilkinson IS, Hardy CJ, Healey G, Karantabiaas G, Johnson N, Kalsson A, Kilgour JD. Association of Inhalation Toxicologists (AIT) working party recommendations for the standard delivery dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhalation Toxicol. 2008;20:1179\u201389.","journal-title":"Inhalation Toxicol"},{"key":"5446_CR27","doi-asserted-by":"crossref","unstructured":"Baker B, Hawser S, Kothari N, Valmont T, Pillar C, Hufnagel D. Poster 501. Investigating the activity of pravibismane against bacterial isolates common in cystic fibrosis pulmonary infections. J Cyst Fibros. 2022;21(Supplement 2):1289.","DOI":"10.1016\/S1569-1993(22)01191-2"},{"key":"5446_CR28","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1128\/AAC.00459-15","volume":"59","author":"A Obreg\u00f3n-Henao","year":"2015","unstructured":"Obreg\u00f3n-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, Lenaerts AJ, Ordway DJ. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother. 2015;59:6904\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"5446_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1128\/AAC.42.1.180","volume":"42","author":"LE Bermudez","year":"1998","unstructured":"Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium Populations Resistant to Macrolides during Experimental Chemotherapy. Antimicrob Agents Chemother. 1998;42:180\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"5446_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/infdis\/174.6.1218","volume":"174","author":"LE Bermudez","year":"1996","unstructured":"Bermudez LE, Nash K, Petrofsky M, Young LS, Inderlied CB. Effect of Ethambutol on the emergence of Clarithromycin-Resistant Mycobacterium avium in the beige mouse model. J Infect Dis. 1996;174:1218.","journal-title":"J Infect Dis"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-05446-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:02:17Z","timestamp":1792594937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-05446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5446"],"URL":"https:\/\/doi.org\/10.1186\/s12866-026-05446-1","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the studies were approved by the IACUC of Oregon State University. The studies described on the manuscript were are approved and supervised by the Biosafety Committee of Oregon State University.All the experiments described follow ethical principles.Declaration of Helsinki: Bacteria strains were obtained from National Jewish Health. The collection was established be a support from the Cystic Fibrosis Foundation, and was approved by the Biosafety Committee. The study (create a pathogen collection to benefit research around the world) adhere to the Declaration of Helsinki to the effect in the \u201cEthics approval and consent to participate\u201d section of the Declarations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the author consented in the submission of the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brett Baker is the Head of Microbion Corporation. The remaining of the authors do not have any conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"904"}}